[1] Moreau R,Jalan R,Gines P,et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis[J]. Gastroenterology,2013,144(7):1426-1437.e9. [2] Sarin S K,Choudhury A,Kumar A,et al. Acute-on-chronic liver failure: pathophysiological mechanisms and clinical management[J]. Nat Rev Gastroenterol Hepatol,2026,23(5):411-431. [3] Pompili E,Baldassarre M,Bedogni G,et al. Predictors of clinical trajectories of patients with acutely decompensated cirrhosis. An external validation of the PREDICT study[J]. Liver Int,2024,44(1):72-82. [4] Jalan R,Yurdaydin C,Bajaj J S,et al. Toward an improved definition of acute-on-chronic liver failure[J]. Gastroenterology,2014,147(1):4-10. [5] Sarin S K,Choudhury A,Sharma M K,et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL): an update[J]. Hepatol Int,2019,13(4):353-390. [6] Moreau R,Tonon M,Krag A,et al. EASL Clinical Practice Guidelines on acute-on-chronic liver failure[J]. J Hepatol,2023,79(2):461-491. [7] Bajaj J S,O'Leary J G,Reddy K R,et al. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures[J]. Hepatology,2014,60(1):250-256. [8] Karvellas C J,Bajaj J S,Kamath P S,et al. AASLD Practice Guidance on acute-on-chronic liver failure and the management of critically ill patients with cirrhosis[J]. Hepatology,2024,79(6):1463-1502. [9] Choudhury A,Kulkarni A V,Arora V,et al. Acute-on-chronic liver failure (ACLF): the 'Kyoto Consensus'-steps from Asia[J]. Hepatol Int,2025,19(1):1-69. [10] Wu T,Li J,Shao L,et al. Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure[J]. Gut,2018,67(12):2181-2191. [11] 张译之, 陈煜. 慢加急性肝衰竭定义、临床特征、治疗与预后的异质性探讨[J]. 肝脏, 2021, 26(10): 1072-1074. [12] 中华医学会肝病学分会重型肝病与人工肝学组, 中华医学会肝病学分会终末期肝病营养与再生学组. 慢加急性肝衰竭诊治指南(2025年版)[J]. 中华肝脏病杂志, 2025, 33(4): 329-339. [13] Kulkarni A V,Sarin S K. Acute-on-chronic liver failure-steps towards harmonization of the definition![J]. J Hepatol,2024,81(2):360-366. [14] Gustot T,Fernandez J,Garcia E,et al. Clinical course of acute-on-chronic liver failure syndrome and effects on prognosis[J]. Hepatology,2015,62(1):243-252. [15] Trebicka J,Fernandez J,Papp M,et al. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology[J]. J Hepatol,2020,73(4):842-854. [16] Engelmann C,Verma N,Qi T,et al. Development and validation of the A-TANGO organ failure score for acute-on-chronic liver failure in global cohorts[J]. J Hepatol,2026,85(1):91-105. [17] Taru V,Szabo G,Mehal W,et al. Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation[J]. J Hepatol,2024,81(5):895-910. [18] Claria J,Stauber R E,Coenraad M J,et al. Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on-chronic liver failure[J]. Hepatology,2016,64(4):1249-1264. [19] Ortega-Ribera M,Brenig R,Bernsmeier C,et al. Uncovering immune dysfunction in ACLF: cellular mechanisms, molecular pathways, and therapeutic frontiers[J]. J Hepatol,2026,85(3):612-629. [20] Yu X,Yang F,Shen Z,et al. BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4(+) T-cell exhaustion[J]. Nat Commun,2024,15(1):1835 [21] Wu Z,Shi H,Zhang L,et al. Comparative analysis of monocyte-derived dendritic cell phenotype and T cell stimulatory function in patients with acute-on-chronic liver failure with different clinical parameters[J]. Front Immunol,2023,14:1290445. [22] Peng B,Li H,Liu K,et al. Intrahepatic macrophage reprogramming associated with lipid metabolism in hepatitis B virus-related acute-on-chronic liver failure[J]. J Transl Med,2023,21(1):419. [23] Yu X,Tian W,Bao X,et al. Dissecting the liver inflammation ecosystem identifies annexin A1 as a pro-resolving target for liver failure[J]. Hepatology,2026,83(5):1174-1191. [24] Badal B D,Cox I J,Bajaj J S. Are we ready to translate metabolomics into clinical practice for ACLF prediction and diagnosis?[J]. J Hepatol,2023,79(5):1082-1084. [25] Poisson J,Lemoinne S,Boulanger C,et al. Liver sinusoidal endothelial cells: physiology and role in liver diseases[J]. J Hepatol,2017,66(1):212-227. [26] Shetty S,Lalor P F,Adams D H. Liver sinusoidal endothelial cells-gatekeepers of hepatic immunity[J]. Nat Rev Gastroenterol Hepatol,2018,15(9):555-567. [27] Yu X,Liu X,Tan W,et al. The clinical courses of HBV-related acute-on-chronic liver failure and a multi-state model to predict disease evolution[J]. Hepatol Commun,2024,8(1):e0354. [28] Mookerjee R P. Prognosis and biomarkers in acute-on-chronic liver failure[J]. Semin Liver Dis,2016,36(2):127-132. [29] Liang X,Luo J,Zhou Q,et al. Single-cell multimodal analysis reveals the dynamic immunopathogenesis of HBV-ACLF progression[J]. Gut,2026,75(2):367-381. [30] Jalan R,Saliba F,Pavesi M,et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure[J]. J Hepatol,2014,61(5):1038-1047. [31] 刘玉盒, 张樱, 李斌华,等. 新COSSH评分短期动态变化对HBV相关慢加急性肝衰竭患者的预测价值[J]. 肝脏, 2025, 30(6): 796-800. [32] Zhang Y,Tan W,Wang X,et al. Metabolic biomarkers significantly enhance the prediction of HBV-related ACLF occurrence and outcomes[J]. J Hepatol,2023,79(5):1159-1171. [33] Lai J C,Sarin S K,Gines P. From prognostication to therapeutics: four key questions to accelerate the development of therapeutics for patients with acute-on-chronic liver failure[J]. Am J Transplant,2024,24(11):1963-1967. [34] Li J,Liang X,Jiang J,et al. PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF[J]. Gut,2022,71(1):163-175. [35] Trebicka J,Hernaez R,Shawcross D L,et al. Recent advances in the prevention and treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF) and the role of biomarkers[J]. Gut,2024,73(6):1015-1024. |